The worldwide biomarkers market is primarily being driven by the rise in the prevalence of chronic diseases and the advancements in omics technologies, such as proteomics and genomics. Biological indicators known as biomarkers are employed in disease diagnosis, disease progression tracking, and therapy efficacy assessment. Increasing use of biomarkers in medication research and discovery is anticipated to fuel market expansion globally over the course of the forecast period.
Notable elements that are generating chances for biomarkers market players include the rise in funding for biomarker research initiatives and the expansion of the need for non-invasive diagnostic tests. However, it can be costly and time-consuming to create novel biomarker-based diagnostic and treatment approaches. This may make biomarker-based tests and treatments more difficult to access for smaller businesses.
One of the main growth areas for the biomarkers market is the rise in the prevalence of chronic illnesses like cancer, heart disease, neurological conditions, and infectious diseases.
The World Health Organisation (WHO) estimates that chronic illnessesoof which cancer is one of the main causesoaccount for roughly 71% of all fatalities globally.
In order to diagnose and cure diseases, biomarkers are essential. The need for biomarker-based diagnoses and treatments is being driven by the rise in the prevalence of chronic diseases.
This research study includes company annual reports, press releases, and investor presentations; white papers; accredited publications; and articles by reputable authors; websites that meet the gold- and silver-standards; and businesses that manufacture battery separators as well as regulatory agencies, trade directories, databases, and publications with verified authorship. Secondary research was primarily used to gather important data on the industry's supply chain, the total number of key players, market classification, and segmentation according to regional and bottom-level market trends. It has also been utilized to learn about significant changes from a market-focused standpoint.
The complete market was divided into various segments and subsegments after the estimation process described below yielded the overall market size. Where applicable, the market breakdown and data triangulation techniques were used to complete the entire market engineering process and determine the precise statistics for each segment and subsegment. By examining multiple elements and patterns from both the supply and demand sides, the data was triangulated. Additionally, the market was validated by employing both top-down and bottom-up strategies.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide biomarkers market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering biomarkers, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
Biomarkers Market based on Product
• Consumables
• Services
• Software
Biomarkers Market based on Type
• Safety Biomarkers
• Efficacy Biomarkers
• Predictive Biomarkers
• Surrogate Biomarkers
• Pharmacodynamics Biomarkers
• Prognostic Biomarkers
• Validation Biomarkers
Biomarkers Market based on Application
• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Other Applications
Biomarkers Market based on Disease Indication
• Cancer
• Infectious Diseases
• Immune Disorders
• Neurological Disorders
• Cardiovascular Disorders
• Other Disease Indications
Biomarkers Market based on Geography
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
In the worldwide biomarkers market by type, the Safety Biomarkers segment held the leading market share in 2019. The main cause of safety biomarkers' large market share is their growing application in the drug-discovery process. During the estimate period, it is anticipated that other variables, such as increased expenditure in research and development to create novel diagnostic processes, will lead to an increase in the use of safety biomarkers.
The forecast period's largest compound annual growth rate (CAGR) is expected for efficacy biomarkers, mostly as a result of upcoming new product launches.
One of the disorders that is studied the most in the world is cancer. Ongoing studies in the field of cancer have shown that the application of biomarkers in the early identification of the fatal illness can be a game-changer for cancer treatment. It is anticipated that a strong product pipeline from leading producers of cancer biomarkers will increase the acceptance of these tools in cancer treatment. The segment for neurological diseases is expected to grow at a notable CAGR in the coming years.
Because biomarkers can help scale up the clinical development stage, their usage in drug discovery and development is constantly increasing. The rise of the drug discovery and development segment is attributed to these causes.
The study examines the main developments and trends in biomarker products in several geographic areas, such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Geographically, North America dominates the biomarkers market because of the region's high cancer incidence and advanced healthcare system. Conversely, Asia-Pacific is expected to grow at a faster rate because to increased investment in research & development by major industry players and government measures to support the biopharmaceutical sector.
The firms in the global biomarkers market that priorities research and development are anticipated to hold the top spot. The top players in the worldwide biomarkers market include Abbott, Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., Qiagen, Epigenomics AG, Abbott, Agilent Technologies, Inc., and Thermo Fisher Scientific, Inc.
• This report illustrates the most vital attributes of the Biomarkers Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Biomarkers Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Biomarkers Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Biomarkers Market.
Table of Contents 1. Executive Summary 2. Industry Outlook 2.1. Industry Overview 2.2. Industry Trends 3. Market Snapshot 3.1. Market Definition 3.2. Market Outlook 3.2.1. Porter Five Forces 3.3. Related Markets 4. Market characteristics 4.1. Market Overview 4.2. Market Segmentation 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. DRO - Impact Analysis 5. Product Type: Market Size & Analysis 5.1. Overview 5.2. Consumables 5.3. Services 5.4. Software 6. Type: Market Size & Analysis 6.1. Overview 6.2. Safety Biomarkers 6.3. Efficacy Biomarkers 6.4. Predictive Biomarkers 6.5. Surrogate Biomarkers 6.6. Pharmacodynamics Biomarkers 6.7. Prognostic Biomarkers 6.8. Validation Biomarkers 7. Application: Market Size & Analysis 7.1. Overview 7.2. Diagnostics 7.3. Drug Discovery & Development 7.4. Personalized Medicine 7.5. Disease Risk Assessment 7.6. Other Applications 8. Disease Indication: Market Size & Analysis 8.1. Overview 8.2. Cancer 8.3. Infectious Diseases 8.4. Immune Disorders 8.5. Neurological Disorders 8.6. Cardiovascular Disorders 8.7. Other Disease Indications 9. Geography: Market Size & Analysis 9.1. Overview 9.2. North America (U.S., Mexico, Canada) 9.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe) 9.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC) 9.5. Latin America (Brazil, Argentina) 9.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa) 10. Competitive Landscape 10.1. Competitor Comparison Analysis 10.2. Market Developments 10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships 10.2.2. Product Launches and execution 11. Vendor Profiles 11.1. Ge Healthcare 11.1.1. Overview 11.1.2. Financial Overview 11.1.3. Product Offerings 11.1.4. Developments 11.1.5. Business Strategy 11.2. Bio-Rad Laboratories 11.2.1. Overview 11.2.2. Financial Overview 11.2.3. Product Offerings 11.2.4. Developments 11.2.5. Business Strategy 11.3. Eisai Co. Ltd. 11.3.1. Overview 11.3.2. Financial Overview 11.3.3. Product Offerings 11.3.4. Developments 11.3.5. Business Strategy 11.4. Abbott Laboratories, Inc. 11.4.1. Overview 11.4.2. Financial Overview 11.4.3. Product Offerings 11.4.4. Developments 11.4.5. Business Strategy 11.5. Thermo Fisher Scientific Inc. 11.5.1. Overview 11.5.2. Financial Overview 11.5.3. Product Offerings 11.5.4. Developments 11.5.5. Business Strategy 11.6. Agilent Technologies Inc. 11.6.1. Overview 11.6.2. Financial Overview 11.6.3. Product Offerings 11.6.4. Developments 11.6.5. Business Strategy 11.7. Roche Diagnostics Limited 11.7.1. Overview 11.7.2. Financial Overview 11.7.3. Product Offerings 11.7.4. Developments 11.7.5. Business Strategy 11.8. Aushon Biosystem 11.8.1. Overview 11.8.2. Financial Overview 11.8.3. Product Offerings 11.8.4. Developments 11.8.5. Business Strategy 11.9. Epistem Ltd. 11.9.1. Overview 11.9.2. Financial Overview 11.9.3. Product Offerings 11.9.4. Developments 11.9.5. Business Strategy 11.10. Siemens AG 11.10.1. Overview 11.10.2. Financial Overview 11.10.3. Product Offerings 11.10.4. Developments 11.10.5. Business Strategy 12. Analyst Opinion 13. Annexure 13.1. Report Scope 13.2. Market Definitions 13.3. Research Methodology 13.3.1. Data Collation and In-house Estimation 13.3.2. Market Triangulation 13.3.3. Forecasting 13.4. Report Assumptions 13.5. Declarations 13.6. Stakeholders 13.7. Abbreviations
Tables TABLE 1. BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 2. BIOMARKERS MARKET VALUE FOR CONSUMABLES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 3. BIOMARKERS MARKET VALUE FOR SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 4. BIOMARKERS MARKET VALUE FOR SOFTWARE, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 5. BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 6. BIOMARKERS MARKET VALUE FOR SAFETY BIOMARKERS, 2021-2030 (USD BILLION) TABLE 7. BIOMARKERS MARKET VALUE FOR EFFICACY BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 8. BIOMARKERS MARKET VALUE FOR PREDICTIVE BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 9. BIOMARKERS MARKET VALUE FOR SURROGATE BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 10. BIOMARKERS MARKET VALUE FOR PHARMACODYNAMICS BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 11. BIOMARKERS MARKET VALUE FOR VALIDATION BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 12. BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 13. BIOMARKERS MARKET VALUE FOR DIAGNOSTICS, 2021-2030 (USD BILLION) TABLE 14. BIOMARKERS MARKET VALUE FOR DRUG DISCOVERY & DEVELOPMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 15. BIOMARKERS MARKET VALUE FOR PERSONALIZED MEDICINE, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 16. BIOMARKERS MARKET VALUE FOR DISEASE RISK ASSESSMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 17. BIOMARKERS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 18. BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 19. BIOMARKERS MARKET VALUE FOR CANCER, 2021-2030 (USD BILLION) TABLE 20. BIOMARKERS MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 21. BIOMARKERS MARKET VALUE FOR IMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 22. BIOMARKERS MARKET VALUE FOR NEUROLOGICAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 23. BIOMARKERS MARKET VALUE FOR CARDIOVASCULAR DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 24. NORTH AMERICA BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 25. NORTH AMERICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 26. NORTH AMERICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 27. NORTH AMERICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 28. U.S BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 29. U.S BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 30. U.S BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 31. U.S BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 32. CANADA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 33. CANADA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 34. CANADA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 35. CANADA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 36. MEXICO BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 37. MEXICO BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 38. MEXICO BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 39. MEXICO BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 40. EUROPE BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 41. EUROPE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 42. EUROPE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 43. EUROPE BIOMARKERS MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION) TABLE 44. EUROPE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 45. GERMANY BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 46. GERMANY BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 47. GERMANY BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 48. GERMANY BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 49. U.K BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 50. U.K BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 51. U.K BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 52. U.K BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 53. FRANCE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 54. FRANCE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 55. FRANCE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 56. FRANCE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 57. ITALY BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 58. ITALY BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 59. ITALY BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 60. ITALY BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 61. SPAIN BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 62. SPAIN BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 63. SPAIN BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 64. SPAIN BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 65. ROE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 66. ROE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 67. ROE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 68. ROE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 69. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 70. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 71. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 72. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 73. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 74. CHINA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 75. CHINA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 76. CHINA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 77. CHINA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 78. INDIA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 79. INDIA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 80. INDIA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 81. INDIA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 82. JAPAN BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 83. JAPAN BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 84. JAPAN BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 85. JAPAN BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 86. REST OF APAC BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 87. REST OF APAC BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 88. REST OF APAC BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 89. REST OF APAC BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 90. LATIN AMERICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 91. LATIN AMERICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 92. LATIN AMERICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 93. LATIN AMERICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 94. BRAZIL BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 95. BRAZIL BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 96. BRAZIL BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 97. BRAZIL BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 98. ARGENTINA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 99. ARGENTINA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 100. ARGENTINA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 101. ARGENTINA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 102. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 103. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 104. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 105. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 106. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 107. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 108. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 109. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 110. UAE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 111. UAE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 112. UAE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 113. UAE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 114. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 115. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) TABLE 116. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 117. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) TABLE 118. GE HEALTHCARE: FINANCIALS TABLE 119. GE HEALTHCARE: PRODUCTS & SERVICES TABLE 120. GE HEALTHCARE: RECENT DEVELOPMENTS TABLE 121. BIO-RAD LABORATORIES: FINANCIALS TABLE 122. BIO-RAD LABORATORIES: PRODUCTS & SERVICES TABLE 123. BIO-RAD LABORATORIES: RECENT DEVELOPMENTS TABLE 124. EISAI CO. LTD.: FINANCIALS TABLE 125. EISAI CO. LTD.: PRODUCTS & SERVICES TABLE 126. EISAI CO. LTD.: RECENT DEVELOPMENTS TABLE 127. ABBOTT LABORATORIES, INC.: FINANCIALS TABLE 128. ABBOTT LABORATORIES, INC.: PRODUCTS & SERVICES TABLE 129. ABBOTT LABORATORIES, INC.: RECENT DEVELOPMENTS TABLE 130. THERMO FISHER SCIENTIFIC INC.: FINANCIALS TABLE 131. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES TABLE 132. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS TABLE 133. AGILENT TECHNOLOGIES INC.: FINANCIALS TABLE 134. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES TABLE 135. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS TABLE 136. ROCHE DIAGNOSTICS LIMITED: FINANCIALS TABLE 137. ROCHE DIAGNOSTICS LIMITED: PRODUCTS & SERVICES TABLE 138. ROCHE DIAGNOSTICS LIMITED: DEVELOPMENTS TABLE 139. AUSHON BIOSYSTEM: FINANCIALS TABLE 140. AUSHON BIOSYSTEM: PRODUCTS & SERVICES TABLE 141. AUSHON BIOSYSTEM: RECENT DEVELOPMENTS TABLE 142. EPISTEM LTD.: FINANCIALS TABLE 143. EPISTEM LTD.: PRODUCTS & SERVICES TABLE 144. EPISTEM LTD.: RECENT DEVELOPMENTS TABLE 145. SIEMENS AG: FINANCIALS TABLE 146. SIEMENS AG: PRODUCTS & SERVICES TABLE 147. SIEMENS AG: RECENT DEVELOPMENTS Charts CHART. 1. BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 2. BIOMARKERS MARKET VALUE FOR CONSUMABLES, BY GEOGRAPHY , 2021-2030 (USD BILLION) CHART. 3. BIOMARKERS MARKET VALUE FOR SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 4. BIOMARKERS MARKET VALUE FOR SOFTWARE, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 5. BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 6. BIOMARKERS MARKET VALUE FOR SAFETY BIOMARKERS, 2021-2030 (USD BILLION) CHART. 7. BIOMARKERS MARKET VALUE FOR EFFICACY BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 8. BIOMARKERS MARKET VALUE FOR PREDICTIVE BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 9. BIOMARKERS MARKET VALUE FOR SURROGATE BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 10. BIOMARKERS MARKET VALUE FOR PHARMACODYNAMICS BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 11. BIOMARKERS MARKET VALUE FOR VALIDATION BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 12. BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 13. BIOMARKERS MARKET VALUE FOR DIAGNOSTICS, 2021-2030 (USD BILLION) CHART. 14. BIOMARKERS MARKET VALUE FOR DRUG DISCOVERY & DEVELOPMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 15. BIOMARKERS MARKET VALUE FOR PERSONALIZED MEDICINE, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 16. BIOMARKERS MARKET VALUE FOR DISEASE RISK ASSESSMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 17. BIOMARKERS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 18. BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 19. BIOMARKERS MARKET VALUE FOR CANCER, 2021-2030 (USD BILLION) CHART. 20. BIOMARKERS MARKET VALUE FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 21. BIOMARKERS MARKET VALUE FOR IMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 22. BIOMARKERS MARKET VALUE FOR NEUROLOGICAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 23. BIOMARKERS MARKET VALUE FOR CARDIOVASCULAR DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) CHART. 24. NORTH AMERICA BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 25. NORTH AMERICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 26. NORTH AMERICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 27. NORTH AMERICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 28. U.S BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 29. U.S BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 30. U.S BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 31. U.S BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 32. CANADA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 33. CANADA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 34. CANADA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 35. CANADA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 36. MEXICO BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 37. MEXICO BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 38. MEXICO BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 39. MEXICO BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 40. EUROPE BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 41. EUROPE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 42. EUROPE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 43. EUROPE BIOMARKERS MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION) CHART. 44. EUROPE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 45. GERMANY BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 46. GERMANY BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 47. GERMANY BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 48. GERMANY BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 49. U.K BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 50. U.K BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 51. U.K BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 52. U.K BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 53. FRANCE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 54. FRANCE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 55. FRANCE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 56. FRANCE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 57. ITALY BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 58. ITALY BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 59. ITALY BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 60. ITALY BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 61. SPAIN BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 62. SPAIN BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 63. SPAIN BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 64. SPAIN BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 65. ROE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 66. ROE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 67. ROE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 68. ROE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 69. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) CHART. 70. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 71. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 72. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 73. ASIA PACIFIC BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 74. CHINA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 75. CHINA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 76. CHINA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 77. CHINA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 78. INDIA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 79. INDIA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 80. INDIA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 81. INDIA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 82. JAPAN BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 83. JAPAN BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 84. JAPAN BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 85. JAPAN BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 86. REST OF APAC BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 87. REST OF APAC BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 88. REST OF APAC BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 89. REST OF APAC BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 90. LATIN AMERICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 91. LATIN AMERICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 92. LATIN AMERICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 93. LATIN AMERICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 94. BRAZIL BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 95. BRAZIL BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 96. BRAZIL BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 97. BRAZIL BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 98. ARGENTINA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 99. ARGENTINA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 100. ARGENTINA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 101. ARGENTINA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 102. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 103. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 104. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 105. MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 106. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 107. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 108. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 109. SAUDI ARABIA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 110. UAE BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 111. UAE BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 112. UAE BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 113. UAE BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 114. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) CHART. 115. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION) CHART. 116. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) CHART. 117. REST OF MIDDLE EAST AND AFRICA BIOMARKERS MARKET VALUE, BY DISEASE INDICATION, 2021-2030 (USD BILLION) CHART. 118. GE HEALTHCARE: FINANCIALS CHART. 119. GE HEALTHCARE: PRODUCTS & SERVICES CHART. 120. GE HEALTHCARE: RECENT DEVELOPMENTS CHART. 121. BIO-RAD LABORATORIES: FINANCIALS CHART. 122. BIO-RAD LABORATORIES: PRODUCTS & SERVICES CHART. 123. BIO-RAD LABORATORIES: RECENT DEVELOPMENTS CHART. 124. EISAI CO. LTD.: FINANCIALS CHART. 125. EISAI CO. LTD.: PRODUCTS & SERVICES CHART. 126. EISAI CO. LTD.: RECENT DEVELOPMENTS CHART. 127. ABBOTT LABORATORIES, INC.: FINANCIALS CHART. 128. ABBOTT LABORATORIES, INC.: PRODUCTS & SERVICES CHART. 129. ABBOTT LABORATORIES, INC.: RECENT DEVELOPMENTS CHART. 130. THERMO FISHER SCIENTIFIC INC.: FINANCIALS CHART. 131. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES CHART. 132. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS CHART. 133. AGILENT TECHNOLOGIES INC.: FINANCIALS CHART. 134. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES CHART. 135. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS CHART. 136. ROCHE DIAGNOSTICS LIMITED: FINANCIALS CHART. 137. ROCHE DIAGNOSTICS LIMITED: PRODUCTS & SERVICES CHART. 138. ROCHE DIAGNOSTICS LIMITED: DEVELOPMENTS CHART. 139. AUSHON BIOSYSTEM: FINANCIALS CHART. 140. AUSHON BIOSYSTEM: PRODUCTS & SERVICES CHART. 141. AUSHON BIOSYSTEM: RECENT DEVELOPMENTS CHART. 142. EPISTEM LTD.: FINANCIALS CHART. 143. EPISTEM LTD.: PRODUCTS & SERVICES CHART. 144. EPISTEM LTD.: RECENT DEVELOPMENTS CHART. 145. SIEMENS AG: FINANCIALS CHART. 146. SIEMENS AG: PRODUCTS & SERVICES CHART. 147. SIEMENS AG: RECENT DEVELOPMENTS
Publisher: IHR Insights
Related Reports
- Global Classic Car Insurance Market (2024 Edition): Analysis By Vehicle Type (Vintage, and Classic), By Ownership Status, By Channel, By Region, By Country: Market Insights and Forecast (2019-2029)
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market based on By Type (Autologous Stem Cells and Autologous Non-Stem cells), Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, and Other Applications), End User (Hospitals, Ambulatory Surgical Centers, and Research Facilities), Regional Outlook- Global Forecast up to 2030
- Biomarkers Market based on By Type (Validation, Efficacy, and Safety), By Disease (Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, and Others), By Application (Personalized Medicines, Drug Discovery & Development, Diagnostics, and Others) - Global Industry Analysis, Trends, Growth, Segment Forecasts, Regional Outlook- Global Forecast up to 2030
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support